GLP-1 receptor agonist weight-loss drugs such as semaglutide may protect the cardiovascular system independent of weight loss.
“Researchers recorded heart attacks, strokes, and cardiovascular deaths (collectively known as major adverse cardiovascular events, or MACE) and repeatedly measured body weight and waist circumference. Here is what they found: Semaglutide lowered the risk of MACE by about 20% versus placebo.”